On 30 June 2026, Skyhawk Therapeutics shared further 12-month data from the ongoing phase 1/2 trial of SKY-0515 (also being tested in the EHDN-endorsed phase 2/3 study). Utilising a propensity score-weighted comparison – using Enroll-HD and TRACK-HD natural history datasets – favourable and consistent trends for participants receiving SKY-0515 were found across the four cUHDRS […]
Important Dates
no event
Latest News
EHDN Newsletter – 58th edition
EHDN News provides regular updates on the network’s activities and highlights key developments relevant to the Huntington’s disease community. The newsletter is published three times a year (March, July and November). We welcome your comments, suggestions and feedback. Please get in touch at newsletter@ehdn.org or contact Catherine Deeprose, Editor. To receive EHDN News directly in your […]
Earthquake Relief Fund
Factor-H is helping HD families affected by the Earthquake in Venezuela. Any donation goes directly the affected families: factor-h.org […]
Earthquake in Venezuela – June 24, 2026
EHDN joins the global Huntington’s disease community in standing with the people of Venezuela in the aftermath of the earthquakes that struck on Wednesday 24 June. Coming amid ongoing geopolitical and economic uncertainty, this is a further blow to an already vulnerable community – including the families of Zulia, whose generations-long participation in HD […]
DEVISE-HD: Developing EVIdence for AntidepreSsant ChoicE to Treat Depression in Huntington’s Disease
Sponsored by Cardiff University (UK), this double-blind randomised controlled trial (RCT) of sertraline, a selective serotonin reuptake inhibitor, will assess the feasibility of conducting a full-scale RCT of the efficacy of antidepressants in HD. Additionally, it will assess some of the current clinical and methodological uncertainties around the effect of antidepressants on HD disease progression. […]
EHDN Elections 2026
Voting is now open! […]
Behavioral Phenotype Working Group: expert opinion survey
Closing date 01 June 2026 […]
PIVOT-LTE: POSITIVE 24-MONTH INTERIM DATA
On 28 April 2026, PTC Therapeutics hosted a webcast outlining results of the 24-month interim analysis of the PIVOT-LTE long-term extension study of votoplam (formerly PTC518). Following the 12-month randomised placebo-controlled PIVOT-HD trial, participants were eligible to continue to the long-term extension. Participants already receiving 5 mg or 10 mg of votoplam continued with the […]
12th Congress of the European Academy of Neurology – Geneva
27 – 30 June 2026: The EAN Congress is one of the leading neurology events worldwide, a hybrid annual meeting uniting clinicians, researchers, educators, industry partners, residents, students, and patient representatives for four days of science and education. […]
EHDN Imaging Working Group (iWG) newsletter – edition 5
The EHDN Imaging Working Group has now produced its fifth newsletter. The newsletter provides relevant updates on imaging studies, research advancements, and innovative techniques in neuroimaging. Imaging Working Group (iWG) NEWSLETTER Edition 5 | March 2026 […]